Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation

  • J Allergy Clin Immunol. 2014 Jan;133(1):270-3.e1-7. doi: 10.1016/j.jaci.2013.08.008.
Kumi Izawa  1 ,  Masamichi Isobe  2 ,  Toshihiro Matsukawa  2 ,  Shinichi Ito  2 ,  Akie Maehara  2 ,  Mariko Takahashi  2 ,  Yoshinori Yamanishi  2 ,  Ayako Kaitani  2 ,  Toshihiko Oki  3 ,  Ko Okumura  4 ,  Toshio Kitamura  5 ,  Jiro Kitaura  6
Affiliations
  • 1. Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan; Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
  • 2. Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • 3. Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan; Division of Stem Cell Signaling, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • 4. Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan; Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan.
  • 5. Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan; Division of Stem Cell Signaling, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. Electronic address: [email protected].
  • 6. Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. Electronic address: [email protected].
PMID: 24035150 DOI: 10.1016/j.jaci.2013.08.008